Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study

• DOI: 10.1186/s12916-022-02433-x
• Publication Date: 2022-07-26T00:02:18Z
• Authors: Maria L. Ricardo-...; Sneha Singh; Lizeth Cifuentes; Paul A. Decker; Daniel Gonzalez-I...; Ann M. Moyer; Maria D. Hurtado; Michael Camilleri; Suzette J. Bielinski; Andres Acosta
• Keywords: Sertraline; Paroxetine; Citalopram; Serotonin reuptake inhibitor

Abstract Background Prescription medications such as selective serotonin reuptake inhibitors (SSRIs), commonly used to treat depression, are associated with weight gain. The role of pharmacogenomics in predicting SSRI-induced gain is unclear. Methods In this retrospective cohort study from participants the Mayo Clinic RIGHT who were prescribed citalopram, paroxetine, sertraline, or fluoxetine, our aim was evaluate association metabolizer phenotype and total body after 6 months SSRIs initiation. We evaluated phenotypes (poor/intermediate, normal, rapid/ultra-rapid) cytochromes P450 enzymes genes: CYP2C9, CYP2C19, CYP2D6 known influence metabolism SSRI medications: CYP2C19 for CYP2C9 fluoxetine. addition, we assessed change at six following prescription using parametric analysis covariance adjusted baseline multivariate regression models. Results poor/intermediate metabolizers citalopram gained significantly more than normal rapid/ultra-rapid (TBWG %: 2.6 [95% CI 1.3—4.1] vs. 0.4 -0.5 – 1.3] -0.1 [-95% -1.5—1.1]; p = 0.001). No significant differences outcomes treatment fluoxetine observed by status. Conclusions Weight may be mediated